As Bitcoin and Ethereum trade significantly below recent peaks, investors face a critical choice. While both present compelling opportunities, a deeper analysis of market dynamics, institutional sentiment, and long-term narratives suggests one digital asset may hold a decisive edge in the current cycle.
A recent 13% quarterly gain offers little solace for long-term shareholders of America's Car-Mart, as the used vehicle retailer's stock remains down 80% over five years amid profitability challenges and revenue growth concerns.
Linde plc (LIN) shares have shown consistent upward momentum, closing recently at $455. While short-term performance is strong, a deeper valuation analysis reveals a complex picture, with divergent views on whether the stock is a bargain or fully priced.
Brendan Banfield's murder trial reaches its climax Friday with closing arguments after he testified he shot a man he found stabbing his wife. Prosecutors allege an elaborate murder-for-hire plot, while the defense claims a tragic act of self-defense.
Despite a premium valuation, AMD is positioning itself as a key challenger in the AI chip race, betting big on integrated data center systems to capture surging demand.
A recent downgrade of Enbridge Inc. by J.P. Morgan analysts has intensified the debate over the pipeline giant's ability to balance future growth with its prized dividend stability, as macroeconomic headwinds pressure its core crude oil segment.
After a challenging year, Pool Corp's shares have shown a notable uptick over the past month, reigniting the debate over its valuation. With a significant gap between its current price and analyst targets, investors are weighing short-term momentum against longer-term headwinds in the housing and outdoor living sectors.
Prime Minister Keir Starmer's landmark visit to Beijing marks a cautious pivot in UK-China relations, yielding agreements on tariffs, visas, and green energy. But can British businesses navigate the opportunities and challenges of re-engagement?
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
Real Matters Inc. (TSE: REAL) kicked off its 2026 fiscal year with robust double-digit revenue growth and a return to profitability, defying typical seasonal headwinds. The company's performance was fueled by market share gains, new client launches, and improved operational efficiency across its U.S. and Canadian segments.
Valero Energy reported a robust fourth quarter, with net income surging to $1.1 billion, driven by strong refining margins and record operational performance. While renewable diesel faced headwinds, ethanol profits soared. The company outlined disciplined capital plans and highlighted potential tailwinds from policy clarity and increased access to discounted heavy crude.
Bitcoin tumbled toward $81,000 as markets reacted to the potential nomination of former Fed Governor Kevin Warsh, whose history of monetary hawkishness is viewed as a headwind for risk assets like cryptocurrency.
Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.
While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
PennyMac Financial Services capped a robust fiscal 2025 with Q4 net income of $107 million, overcoming headwinds from an unexpected wave of mortgage prepayments. While competitive pressures limited margin expansion, CEO David Spector pointed to strategic tech investments and a significant embedded refinance portfolio as catalysts for targeted mid-to-high teens ROE later this year.
Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.
Fastly's stock has surged on the coattails of broader AI and edge computing optimism, but a closer look reveals a complex picture of short-term gains against longer-term struggles. As the market weighs future growth against persistent losses, investors are left questioning if the recent rally has legs.
United States Antimony (UAMY) faces a volatile market reaction following Washington's reported reversal on critical mineral price supports, casting uncertainty over its strategic expansion into Bolivia.
